生物学家和工程师们一直在努力寻找帮助遭受这些困难的人们的方法。如果我们看看目前的情况，有两种治疗方法可供失明人士选择，即“药物治疗”和“假肢装置”。药物治疗包括采取特定形式的药物治疗疾病;然而，它很少对人们有帮助。美国食品和药物管理局(FDA)最近批准了一种名为“Luxturna”的治疗视网膜疾病的药物，但它的价格在85万美元左右，这是普通人负担不起的。修复装置为视网膜退行性疾病患者带来了希望，如黄斑变性和色素性视网膜炎，这些疾病影响着全世界数百万人。这些疾病会导致视网膜输入细胞和光感受器的逐渐丧失，从而导致严重的视觉障碍[2]。大多数患者依赖假体设备，它们直接刺激存活的细胞，绕过受损的视网膜组织。这些设备在一定程度上是成功的，它们使患者能够看到明亮/高对比度的区域，这有助于他们从一个地方移动到另一个地方。然而，这些设备还不能给病人提供想要的视觉;因此，需要做更多的事情来改善结果。
英国社会学作业代写 义眼
Biologists and engineers have been working continuously to find out ways to help the people suffering from such difficulties. If we have a look at the current scenario, there are two types of treatments which can be opted by people suffering from blindness, namely ‘drug therapy’ and ‘prosthetic devices. Drug therapy involves taking specific form of medication to cure the disease; however, it is rarely helpful for people. A drug named ‘Luxturna’ has been recently approved by the United States Food and Drug Administration (FDA) to treat the retinal disorder, but it’s priced at around $850,000, which is not affordable for common people. Prosthetic devices offer hope for patients with retinal degenerative diseases, such as macular degeneration and retinitis pigmentosa, which affect millions of people worldwide. These diseases cause a progressive loss of the retina’s input cells and the photoreceptors, which leads to severe visual impairment [2]. Most of the patients rely on prosthetic devices, which directly give stimulation to the surviving cells, bypassing the damaged retinal tissues. These devices have been successful to an extent that they enable the patient to see bright/high contrast areas, which assist them a bit while they are moving from one place to another. However, these devices have not been able to give the desired vision to the patients; hence something more needs to be done to improve the result.
本段内容来自网络 并不是我们的写手作品 请勿直接剽窃，查重100%，造成后果与本站无关。如需定制论文请记得联系我们。
